Granite Investment Partners LLC Purchases New Shares in Cellebrite DI Ltd. $CLBT

Granite Investment Partners LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 615,527 shares of the company’s stock, valued at approximately $11,406,000. Granite Investment Partners LLC owned 0.26% of Cellebrite DI as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of CLBT. Voss Capital LP increased its holdings in shares of Cellebrite DI by 34.0% during the second quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after purchasing an additional 1,306,398 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new position in Cellebrite DI during the 3rd quarter worth $19,457,000. Handelsbanken Fonder AB raised its holdings in Cellebrite DI by 61.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company’s stock valued at $39,200,000 after acquiring an additional 931,300 shares in the last quarter. Thematics Asset Management acquired a new position in Cellebrite DI in the 2nd quarter valued at $13,919,000. Finally, Qube Research & Technologies Ltd lifted its position in shares of Cellebrite DI by 93.7% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,500,505 shares of the company’s stock valued at $24,008,000 after acquiring an additional 725,679 shares during the period. Institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on CLBT. Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Lake Street Capital raised their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Bank of America upped their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Cellebrite DI Trading Down 4.5%

CLBT stock opened at $13.16 on Monday. The firm has a 50-day moving average price of $16.59 and a 200-day moving average price of $17.03. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $20.86. The stock has a market capitalization of $3.15 billion, a P/E ratio of 42.45, a price-to-earnings-growth ratio of 2.02 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.14. The business had revenue of $128.82 million during the quarter, compared to analysts’ expectations of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.